



Bresso (Milan), May 10, 2023

RE: Clinical study BT - L-CsA - 201 - SCT BOSTON 4 "A Phase IIa Multi-Center, Randomized, Single-Blind Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation" EudraCT Number 2014-002600-24.

Dear Ethics Committee/Competent Authority,

We are writing to inform you of the voluntary, business-related decision of the sponsor, Zambon SpA (from now Zambon), to close the Boston 4 clinical trial on liposomal cyclosporine.

From the beginning of the trial in December 2019, only 6 patients were enrolled.

Due to the low number of patients recruited so far and the slow enrolment pace of patients, on 18 March 2022, the sponsor decided to terminate the BOSTON-4 safety and tolerability trial early. This decision was made after Zambon performed a careful and due diligent analysis of the current study status and considered the impact of the coronavirus disease 2019 (COVID-19) pandemic on-site activities.

Zambon remains committed to meeting the needs of patients with Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation and to ongoing research in inflammatory respiratory diseases.

If you have any questions or require additional information, please contact Valentina Zanin

email: valentina.zanin@zambongroup.com

Asking for your kind relevant actions.

Kindest regards,

Valentina Zanin,

Clinical Trial Manager

Zambon USA Ltd.